Amivantamab (FUT8-KO) is a recombinant anti-EGFR-MET monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). The absence of fucose on this antibody significantly enhances its Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. Functionally, Amivantamab (FUT8-KO) effectively inhibits ligand binding to EGFR and MET receptors, facilitates the endocytosis and subsequent degradation of receptor-antibody complexes, and promotes Fc-dependent cytokinesis in macrophages as well as ADCC in natural killer cells. This antibody is pivotal for research focused on the molecular mechanisms of cancer cell signaling and immune response modulation.
Amivantamab (FUT8-KO) is a recombinant anti-EGFR-MET monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). The absence of fucose on this antibody significantly enhances its Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. Functionally, Amivantamab (FUT8-KO) effectively inhibits ligand binding to EGFR and MET receptors, facilitates the endocytosis and subsequent degradation of receptor-antibody complexes, and promotes Fc-dependent cytokinesis in macrophages as well as ADCC in natural killer cells. This antibody is pivotal for research focused on the molecular mechanisms of cancer cell signaling and immune response modulation.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
